Krystal Biotech Stock
StockStockPrice
Frequently asked questions
What is Krystal Biotech's market capitalization?
What is Krystal Biotech's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Krystal Biotech?
What are the analyst ratings and target price for Krystal Biotech's stock?
What is Krystal Biotech's revenue over the trailing twelve months?
What is the EBITDA for Krystal Biotech?
What is the free cash flow of Krystal Biotech?
What is the 5-year beta of Krystal Biotech's stock?
How many employees does Krystal Biotech have, and what sector and industry does it belong to?
What is the free float of Krystal Biotech's shares?
Financials
Market Cap
$5.63B5Y beta
0.79EPS (TTM)
$1.767Free Float
25.22MP/E ratio (TTM)
110.83Revenue (TTM)
$241.52MEBITDA (TTM)
$71.99MFree Cashflow (TTM)
$58.06MPricing
Analyst Ratings
The price target is $189.00 and the stock is covered by 10 analysts.
Buy
10
Hold
0
Sell
0
Information
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
229
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker